NEWS!
- 16/05/2023
Recent technical developments such as the online activity monitoring during implantation and the definition of Key Performance Indicators for MEDICIS were reported at EMIS2022 and IPAC2023 conferences. Related EMIS and IPAC publications.
- 10/03/2023
Three new project proposals were submitted at the 10th MEDICIS Collaboration board, with a notable request to translate one of the MEDICIS High Molar Activity radionuclides in a clinical settings.
- 15/11/2022
The Frontiers Research Topics : MEDICIS-Promed, Advances in Radioactive Ion Beams for Nuclear Medicine is now published. It can be downloaded from there.
- 26/09/2022
The half-life of Tb-155 produced at MEDICIS has been revised and is now published by S. Collins et al. in Applied Radiation and Isotope. High molar activity Sm-153 was 1st used in Targeted Radionuclide Therapy and theranostics (MED-025) by M. Ooms et al, as presented at TERACHEM.
JOB OPPORTUNITIES
- Please check out regularly
A KNOWLEDGE TRANSFER SUCCESS STORY
GRANTS & DONATIONS - CERN & Society Foundation
The CERN KT-Fund
La Fondation pour l'innovation sur le cancer et la biologie
The ADAM company
The FWO
